More and more clinical guidelines have recommended use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, to prevent major adverse cardiovascular and renal events in patients with type 2 diabetes, heart failure, and/or chronic kidney disease. This evidence concerns the gene SLC5A2 and chronic kidney disease.